At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,574 enrolled
Drug / intervention
Vandetanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Vandetanib and Erlotinib for Non Small Cell Lung Cancer. Completed, enrolled 1,574 participants across 153 sites in 22 countries.
Detailed Summary
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesArgentina, Australia, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, India, Indonesia, Italy, Mexico, Netherlands, Norway, Philippines, South Korea, Spain, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2006
Primary CompletionSep 2008
Study CompletionNov 2016
TodayJul 2026
First PostedAug 15, 2006
Enrollment StartAug 1, 2006
Primary CompletionSep 1, 2008
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.9 years ago
Interventions
Vandetanibdrug
once daily oral tablet
Erlotinibdrug
oral dose